Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Biomarker profiles associated with reverse ventricular remodelling in patients with heart failure and a reduced ejection fraction: Insights from the echocardiographic substudy of the VICTORIA trial

J. Tromp, CSP. Lam, W. Alemayehu, CR. de Filippi, V. Melenovský, K. Sliwa, Y. Lopatin, JL. Arango, MC. Bahit, L. Roessig, CM. O'Connor, P. Shah, CM. Westerhout, AA. Voors, B. Pieske, PW. Armstrong, VICTORIA Study Group

. 2024 ; 26 (10) : 2231-2239. [pub] 20240730

Language English Country England, Great Britain

Document type Journal Article, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc25004045

Grant support
Merck
Bayer

AIMS: Reverse ventricular remodelling, defined as a decrease in left ventricular end-systolic volume indexed to body surface area (LVESVI) or an increase in left ventricular ejection fraction (LVEF), is associated with improved clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF). However, the underlying pathophysiological mechanisms remain unclear. METHODS AND RESULTS: We evaluated paired core-lab assessed echocardiograms and measurements of 92 biomarkers at baseline and 8 months thereafter in 419 participants with HFrEF. Reverse ventricular remodelling was defined as a >5% LVEF increase or >15% LVESVI relative decrease between baseline and 8 months. We evaluated the association between baseline biomarkers and their changes with reverse ventricular remodelling in the prospectively randomized controlled VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) trial. Of 419 patients (median age 66 [interquartile range 57-74] years, 27.4% women), 206 (49.2%) had reverse ventricular remodelling (either a 5% LVEF increase or a 15% LVESVI decrease). There were no differences in baseline biomarker concentrations between patients with versus those without reverse ventricular remodelling on follow-up. However, in patients with reverse ventricular remodelling there were significant decreases in biomarkers relating to inflammation and cardiac metabolism; particularly the tumour necrosis factor superfamily member 13B (ratio 0.82, 95% confidence interval [CI] 0.77-0.88), growth differentiation factor-15 (ratio 0.74, 95% CI 0.66-0.84), and insulin-like growth factor binding protein 7 (ratio 0.80, 95% CI 0.73-0.88). CONCLUSIONS: Reverse ventricular remodelling in patients with HFrEF is associated with a decrease of biomarkers related to inflammation and cardiac metabolism.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25004045
003      
CZ-PrNML
005      
20250206105100.0
007      
ta
008      
250121s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ejhf.3397 $2 doi
035    __
$a (PubMed)39078607
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Tromp, Jasper $u Saw Swee Hock School of Public Health National University of Singapore and National University of Singapore and National University Health System, Singapore, Singapore $u National Heart Centre Singapore, Duke-National University of Singapore, Singapore, Singapore $u Department of Cardiology, University Medical Centre Groningen, Groningen, The Netherlands
245    10
$a Biomarker profiles associated with reverse ventricular remodelling in patients with heart failure and a reduced ejection fraction: Insights from the echocardiographic substudy of the VICTORIA trial / $c J. Tromp, CSP. Lam, W. Alemayehu, CR. de Filippi, V. Melenovský, K. Sliwa, Y. Lopatin, JL. Arango, MC. Bahit, L. Roessig, CM. O'Connor, P. Shah, CM. Westerhout, AA. Voors, B. Pieske, PW. Armstrong, VICTORIA Study Group
520    9_
$a AIMS: Reverse ventricular remodelling, defined as a decrease in left ventricular end-systolic volume indexed to body surface area (LVESVI) or an increase in left ventricular ejection fraction (LVEF), is associated with improved clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF). However, the underlying pathophysiological mechanisms remain unclear. METHODS AND RESULTS: We evaluated paired core-lab assessed echocardiograms and measurements of 92 biomarkers at baseline and 8 months thereafter in 419 participants with HFrEF. Reverse ventricular remodelling was defined as a >5% LVEF increase or >15% LVESVI relative decrease between baseline and 8 months. We evaluated the association between baseline biomarkers and their changes with reverse ventricular remodelling in the prospectively randomized controlled VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) trial. Of 419 patients (median age 66 [interquartile range 57-74] years, 27.4% women), 206 (49.2%) had reverse ventricular remodelling (either a 5% LVEF increase or a 15% LVESVI decrease). There were no differences in baseline biomarker concentrations between patients with versus those without reverse ventricular remodelling on follow-up. However, in patients with reverse ventricular remodelling there were significant decreases in biomarkers relating to inflammation and cardiac metabolism; particularly the tumour necrosis factor superfamily member 13B (ratio 0.82, 95% confidence interval [CI] 0.77-0.88), growth differentiation factor-15 (ratio 0.74, 95% CI 0.66-0.84), and insulin-like growth factor binding protein 7 (ratio 0.80, 95% CI 0.73-0.88). CONCLUSIONS: Reverse ventricular remodelling in patients with HFrEF is associated with a decrease of biomarkers related to inflammation and cardiac metabolism.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    12
$a srdeční selhání $x patofyziologie $7 D006333
650    12
$a tepový objem $x fyziologie $7 D013318
650    12
$a remodelace komor $x fyziologie $7 D020257
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    12
$a biologické markery $7 D015415
650    12
$a echokardiografie $x metody $7 D004452
650    _2
$a funkce levé komory srdeční $x fyziologie $7 D016277
650    _2
$a prospektivní studie $7 D011446
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Lam, Carolyn S P $u National Heart Centre Singapore, Duke-National University of Singapore, Singapore, Singapore
700    1_
$a Alemayehu, Wendimagegn $u University of Alberta, Canadian VIGOUR Centre, Edmonton, AB, Canada
700    1_
$a de Filippi, Christopher R $u The Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, VA, USA
700    1_
$a Melenovský, Vojtěch $u Department of Cardiology, Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic
700    1_
$a Sliwa, Karen $u Hatter Institute for Cardiovascular Research in Africa, Faculty of Health Sciences, Department of Medicine and Cardiology, University of Cape Town, Cape Town, South Africa
700    1_
$a Lopatin, Yuri $u Volgograd State Medical University, Regional Cardiology Centre Volgograd, Volgograd, Russian Federation
700    1_
$a Arango, Juan Luis $u Unidad de Cirugía Cardiovascular de Guatemala, Guatemala City, Guatemala
700    1_
$a Bahit, M Cecilia $u INECO Neurociencias Oroño, Fundación INECO, Rosario, Argentina
700    1_
$a Roessig, Lothar $u Bayer AG, Wuppertal, Germany
700    1_
$a O'Connor, Christopher M $u The Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, VA, USA
700    1_
$a Shah, Palak $u The Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, VA, USA
700    1_
$a Westerhout, Cynthia M $u University of Alberta, Canadian VIGOUR Centre, Edmonton, AB, Canada
700    1_
$a Voors, Adriaan A $u Department of Cardiology, University Medical Centre Groningen, Groningen, The Netherlands $u University of Groningen, Groningen, The Netherlands
700    1_
$a Pieske, Burkert $u Charité University Medicine, German Heart Center, Berlin, Germany
700    1_
$a Armstrong, Paul W $u University of Alberta, Canadian VIGOUR Centre, Edmonton, AB, Canada
710    2_
$a VICTORIA Study Group
773    0_
$w MED00006634 $t European journal of heart failure $x 1879-0844 $g Roč. 26, č. 10 (2024), s. 2231-2239
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39078607 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206105056 $b ABA008
999    __
$a ok $b bmc $g 2263659 $s 1240052
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 26 $c 10 $d 2231-2239 $e 20240730 $i 1879-0844 $m European journal of heart failure $n Eur J Heart Fail $x MED00006634
GRA    __
$p Merck
GRA    __
$p Bayer
LZP    __
$a Pubmed-20250121

Find record

Citation metrics

Archiving options